ferric citrate has been researched along with deferoxamine in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (29.63) | 18.7374 |
| 1990's | 6 (22.22) | 18.2507 |
| 2000's | 10 (37.04) | 29.6817 |
| 2010's | 2 (7.41) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| de Sousa, M; Giardina, P; Grady, RW; Hilgartner, MW; Porto, G; Reimão, R | 1 |
| Boelaert, JR; Van Cutsem, J | 1 |
| Awai, M; Ogino, T | 1 |
| Cederbaum, AI; Puntarulo, S | 1 |
| Sawas-Dimopoulou, C; Soulpi, C | 1 |
| Jaarsma, EY; Marcelis, JH; van Asbeck, BS; van Kats, JH; Verhoef, J | 1 |
| Marcelis, JH; Marx, JJ; Struyvenberg, A; van Asbeck, BS; van Kats, JH; Verhoef, J | 1 |
| Archibald, FS; DeVoe, IW; Simonson, C | 1 |
| Burkitt, MJ; Kadiiska, MB; Mason, RP; Xiang, QH | 1 |
| Gelfand, EW; Kovár, J; Seligman, P | 1 |
| Sagripanti, JL; Toyokuni, S | 1 |
| Aouad, F; Baret, P; Brissot, P; Caris, C; Crichton, RR; Henry, C; Lescoat, G; Morel, I; Pierre, JL; Rakba, N; Ward, RJ | 1 |
| Hashimoto, K; Hisakawa, N; Matsumori, A; Nishiya, K; Tahara, K | 1 |
| Adrian, GS; Barnum-Huckins, K | 1 |
| Blake, DR; Millar, AD; Rampton, DS | 1 |
| Armstrong, C; Lees, GJ; Leong, W | 1 |
| Labbe, P; Lesuisse, E | 1 |
| Baker, E; Chua, AC; Ingram, HA; Raymond, KN | 1 |
| Hashimoto, K; Hisakawa, N; Nishiya, K; Tahara, K; Wang, H | 1 |
| Harish Kumar, M; Maruyama, M; Omura, S; Radha, KS; Sugiki, M | 1 |
| Harish Kumar, M; Maruyama, M; Omura, S; Radha, KS; Sugiki, M; Yoshida, E | 1 |
| Kwon, TK; Lee, TJ; Park, JW; Woo, KJ | 1 |
| Jang, HJ; Jeon, BH; Jun, CD; Kim, EC; Lee, HJ; Lee, J; Lee, SK | 1 |
| Chung, HT; Jun, CD; Kim, EC; Lee, J; Lee, SK; Lee, W; Lee, YM; Lim, HD; Min, SK; Pae, HO; Won, DH | 1 |
| Eccleston, J; Evans, P; Hider, RC; Kayyali, R; Porter, JB | 1 |
| Fujii, M; Ito, H; Masago, Y; Omura, T; Waite, TD; Yoshimura, C | 1 |
| Bakker, SJL; Dam, WA; de Borst, MH; Eisenga, MF; Gorter, AR; Hoes, MF; van den Born, J; van der Meer, P; Vinke, JSJ | 1 |
1 review(s) available for ferric citrate and deferoxamine
| Article | Year |
|---|---|
Iron and lymphocytes: reciprocal regulatory interactions.
Topics: Animals; Bloodletting; CD4-CD8 Ratio; Chelation Therapy; Deferoxamine; Ferric Compounds; Hemochromatosis; Iron; Mice; Models, Biological; Rats; Rats, Inbred Strains; Rats, Inbred WF; T-Lymphocyte Subsets; Thalassemia | 1991 |
26 other study(ies) available for ferric citrate and deferoxamine
| Article | Year |
|---|---|
Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis).
Topics: Amphotericin B; Animals; Deferoxamine; Ferric Compounds; Guinea Pigs; Iron; Iron Chelating Agents; Male; Mucormycosis; Rhizopus; Stimulation, Chemical | 1989 |
Lipid peroxidation and tissue injury by ferric citrate in paraquat-intoxicated mice.
Topics: Animals; Aspartate Aminotransferases; Deferoxamine; Ethane; Ferric Compounds; Hydroxides; Hydroxyl Radical; Iron; Kidney; Kinetics; Lipid Peroxides; Liver; Male; Mice; NADP; Oxygen; Paraquat; Superoxides; Tissue Distribution; Trichloroacetic Acid | 1988 |
Comparison of the ability of ferric complexes to catalyze microsomal chemiluminescence, lipid peroxidation, and hydroxyl radical generation.
Topics: Adenosine Diphosphate; Animals; Deferoxamine; Edetic Acid; Ferric Compounds; Hydroxides; Hydroxyl Radical; Lipid Peroxides; Luminescent Measurements; Male; Mannitol; Microsomes, Liver; NADP; NADPH-Ferrihemoprotein Reductase; Pentetic Acid; Rats; Rats, Inbred Strains | 1988 |
Alterations of the [59Fe]ferric citrate biodistribution in hyperferremic mice after the administration of pyrophosphate and desferrioxamine.
Topics: Animals; Deferoxamine; Diphosphates; Drug Combinations; Ferric Compounds; Iron; Iron Radioisotopes; Mice; Tissue Distribution | 1983 |
Synergy between the iron chelator deferoxamine and the antimicrobial agents gentamicin, chloramphenicol, cefalothin, cefotiam and cefsulodin.
Topics: Alcaligenes; Bacteria; Cefotaxime; Cefotiam; Cefsulodin; Cephalosporins; Cephalothin; Chloramphenicol; Deferoxamine; Drug Synergism; Enterobacteriaceae; Ferric Compounds; Gentamicins; Pseudomonas; Staphylococcus | 1983 |
Inhibition of bacterial multiplication by the iron chelator deferoxamine: potentiating effect of ascorbic acid.
Topics: Alcaligenes; Ascorbic Acid; Bacteria; Deferoxamine; Dose-Response Relationship, Drug; Drug Synergism; Enterobacteriaceae; Ferric Compounds; Neisseria meningitidis; Pseudomonas; Staphylococcus | 1983 |
Comparison of iron binding and uptake from FeCl3 and Fe-citrated by Neisseria meningitidis.
Topics: Biological Transport, Active; Chlorides; Deferoxamine; Energy Metabolism; Ferric Compounds; Iron; Kinetics; Neisseria meningitidis; Temperature | 1981 |
Iron supplementation generates hydroxyl radical in vivo. An ESR spin-trapping investigation.
Topics: 2,2'-Dipyridyl; 5'-Nucleotidase; Alanine Transaminase; Alkaline Phosphatase; Animal Feed; Animals; Bile Acids and Salts; Cyclic N-Oxides; Deferoxamine; Dimethyl Sulfoxide; Electron Spin Resonance Spectroscopy; Ferric Compounds; Food, Fortified; Hydroxyl Radical; Iron; L-Iditol 2-Dehydrogenase; L-Lactate Dehydrogenase; Liver; Male; Nitrogen Oxides; Rats; Rats, Sprague-Dawley; Reference Values; Spin Labels | 1995 |
Inhibition of growth of the lymphocyte lines by deferoxamine under various iron-supply conditions.
Topics: Animals; B-Lymphocytes; Cell Count; Cell Division; Culture Media; Deferoxamine; Ferric Compounds; Humans; Mice; T-Lymphocytes; Transferrin; Tumor Cells, Cultured | 1993 |
Induction of oxidative single- and double-strand breaks in DNA by ferric citrate.
Topics: Ascorbic Acid; Catalase; Cysteine; Deferoxamine; DNA Damage; DNA, Superhelical; Ferric Compounds; Free Radical Scavengers; Hydrogen Peroxide; Hydrogen-Ion Concentration; Osmolar Concentration; Plasmids; Superoxides | 1993 |
Iron mobilisation and cellular protection by a new synthetic chelator O-Trensox.
Topics: Animals; Cells, Cultured; Deferoxamine; Ethylamines; Ferric Compounds; Ferritins; Hemosiderin; Hydroxyquinolines; In Vitro Techniques; Iron; Iron Chelating Agents; Iron-Dextran Complex; Liver; Male; Rats; Rats, Wistar | 1998 |
Down regulation by iron of prostaglandin E2 production by human synovial fibroblasts.
Topics: Aged; Arthritis, Rheumatoid; Cells, Cultured; Citric Acid; Deferoxamine; Depression, Chemical; Dinoprostone; Dose-Response Relationship, Drug; Female; Ferric Compounds; Fibroblasts; Humans; Interleukin-1; Iron Chelating Agents; Male; Middle Aged; Osteoarthritis, Knee; Recombinant Proteins; Synovial Membrane | 1998 |
Iron regulation of transferrin synthesis in the human hepatoma cell line HepG2.
Topics: Carcinoma, Hepatocellular; Deferoxamine; Dose-Response Relationship, Drug; Ferric Compounds; Hemin; Humans; Iron; Precipitin Tests; Time Factors; Transferrin; Tumor Cells, Cultured | 2000 |
Effects of iron and iron chelation in vitro on mucosal oxidant activity in ulcerative colitis.
Topics: Adult; Aged; Chelating Agents; Colitis, Ulcerative; Deferoxamine; Female; Ferric Compounds; Humans; Intestinal Mucosa; Luminescent Measurements; Male; Middle Aged; Phenanthrolines; Reactive Oxygen Species | 2000 |
Comparative effects of metal chelating agents on the neuronal cytotoxicity induced by copper (Cu+2), iron (Fe+3) and zinc in the hippocampus.
Topics: Animals; Cell Survival; Chelating Agents; Chlorides; Copper Sulfate; Cytotoxins; Deferoxamine; Edetic Acid; Ethylenediamines; Ferric Compounds; Hippocampus; Male; Neurons; Phenanthrolines; Rats; Rats, Wistar; Zinc | 2001 |
Reductive and non-reductive mechanisms of iron assimilation by the yeast Saccharomyces cerevisiae.
Topics: Aminolevulinic Acid; Culture Media; Deferoxamine; Ferric Compounds; FMN Reductase; Heme; Iron; Iron Chelating Agents; NADH, NADPH Oxidoreductases; Oxidation-Reduction; Saccharomyces cerevisiae | 1989 |
Multidentate pyridinones inhibit the metabolism of nontransferrin-bound iron by hepatocytes and hepatoma cells.
Topics: Animals; Deferiprone; Deferoxamine; Ferric Compounds; Hepatocytes; Iron; Iron Chelating Agents; Iron Radioisotopes; Kinetics; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Molecular Structure; Pyridones; Rats; Rats, Wistar; Tumor Cells, Cultured | 2003 |
Suppressive effect of iron on concanavalin A-induced multinucleated giant cell formation by human monocytes.
Topics: Acid Phosphatase; Antigens, CD; Cell Fusion; Cells, Cultured; Citrates; Concanavalin A; Deferoxamine; Dose-Response Relationship, Drug; Ferric Compounds; Giant Cells; Humans; Intercellular Adhesion Molecule-1; Iron; Isoenzymes; Monocytes; NG-Nitroarginine Methyl Ester; Sodium Citrate; Tartrate-Resistant Acid Phosphatase; Time Factors | 2003 |
Post-transcriptional regulation of plasminogen activator inhibitor-1 by intracellular iron in cultured human lung fibroblasts--interaction of an 81-kDa nuclear protein with the 3'-UTR.
Topics: 3' Untranslated Regions; Antigens; Blotting, Northern; Cell Membrane; Cell Nucleus; Cells, Cultured; Cross-Linking Reagents; Culture Media, Conditioned; Cycloheximide; Cytoplasm; Deferoxamine; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Ferric Compounds; Fibrinolysin; Fibroblasts; Humans; Iron; Lung; Plasmids; Plasminogen Activator Inhibitor 1; Protein Biosynthesis; RNA Processing, Post-Transcriptional; RNA, Messenger; Time Factors; Transcription, Genetic; Ultraviolet Rays; Wound Healing | 2005 |
Iron-mediated stability of PAI-1 mRNA in adenocarcinoma cells-involvement of a mRNA-binding nuclear protein.
Topics: 3' Untranslated Regions; Adenocarcinoma; Cell Line, Tumor; Deferoxamine; Ferric Compounds; Humans; Iron; Iron Chelating Agents; Nuclear Proteins; Plasminogen Activator Inhibitor 1; RNA Stability; RNA-Binding Proteins; RNA, Messenger | 2005 |
Desferrioxamine, an iron chelator, enhances HIF-1alpha accumulation via cyclooxygenase-2 signaling pathway.
Topics: Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Deferoxamine; Ferric Compounds; Flavonoids; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Iron Chelating Agents; Mitogen-Activated Protein Kinases; Signal Transduction; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2006 |
p38 and ERK MAP kinase mediates iron chelator-induced apoptosis and -suppressed differentiation of immortalized and malignant human oral keratinocytes.
Topics: Apoptosis; Caspase 3; Caspase 8; Caspases; Cell Differentiation; Cell Proliferation; Cytochromes c; Deferoxamine; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Ferric Compounds; Flavonoids; Humans; Imidazoles; Iron Chelating Agents; Keratinocytes; Mouth Neoplasms; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Precursors; Pyridines | 2006 |
Iron chelator differentially activates macrophage inflammatory protein-3alpha/CCL20 in immortalized and malignant human oral keratinocytes.
Topics: Carcinoma, Squamous Cell; Chemokine CCL20; Deferoxamine; Enzyme-Linked Immunosorbent Assay; Female; Ferric Compounds; Gene Expression; Humans; Iron Chelating Agents; Keratinocytes; Male; Mouth Neoplasms; NF-kappa B; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tumor Cells, Cultured | 2008 |
Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.
Topics: Adult; Chromatography, High Pressure Liquid; Deferiprone; Deferoxamine; Female; Ferric Compounds; Humans; Iron; Iron Chelating Agents; Iron Overload; Kinetics; Male; Pyridones; Siderophores; Thalassemia; Transferrin; Transfusion Reaction | 2010 |
Mechanism and kinetics of ligand exchange between ferric citrate and desferrioxamine B.
Topics: Deferoxamine; Ferric Compounds; Hydrogen-Ion Concentration; Kinetics; Ligands; Molecular Structure; Thermodynamics | 2011 |
Iron deficiency is related to lower muscle mass in community-dwelling individuals and impairs myoblast proliferation.
Topics: Adult; Animals; Atrophy; Cell Proliferation; Deferoxamine; Female; Ferritins; Humans; Independent Living; Iron; Iron Deficiencies; Male; Mice; Muscles; Myoblasts, Skeletal; Quality of Life; Transferrins | 2023 |